JP Morgan Chase’s bluebird bio BLUE Stock Holding History

JP Morgan Chase’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,316	Closed	-$2.75M	–	5614
2019 Q3	$2.75M	Sell	2,316 -6,755	-74%	-$10.3M	﹤0.01%	3193
2019 Q2	$14.6M	Buy	+9,071	New	+$15.7M	﹤0.01%	1811
2019 Q1	–	Sell	-1,783	Closed	-$2.29M	–	5764
2018 Q4	$2.29M	Buy	1,783 +1,459	+450%	+$2.24M	﹤0.01%	3184
2018 Q3	$613K	Sell	324 -703	-68%	-$1.45M	﹤0.01%	4189
2018 Q2	$2.09M	Sell	1,027 -1,057	-51%	-$2.41M	﹤0.01%	3389
2018 Q1	$4.61M	Hold	2,084	–	–	﹤0.01%	2650
2017 Q4	$4.81M	Buy	+2,084	New	+$4.23M	﹤0.01%	2713

Other funds holding BLUE

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

JP Morgan Chase's BLUE Position: Q2 2025 in Review

JP Morgan Chase sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 26,870 shares — an estimated $131K sold.

JP Morgan Chase first reported a position in BLUE in Q3 2013 and held it in 44 quarters. The position peaked at $52.1M in Q2 2021. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

JP Morgan Chase reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
JP Morgan Chase sold 26,870 bluebird bio shares in Q2 2025, an estimated $131K.
JP Morgan Chase first reported a position in bluebird bio in Q3 2013 and held it in 44 quarters.
JP Morgan Chase's bluebird bio position peaked at $52.1M in Q2 2021.
3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.